Last week Novozymes reported first half revenue from its biopharma business of DKK77m ($13m), up from DKK51m in the comparable period last year, roughly one per cent of the DKK5.8bn of total revenue it recorded in the six months to the end of June 2012.
Novozymes said that growth was achieved despite the divestiture of its biopharma unit in Sweden to Repligen late last year, citing increased sales of recombinant albumin, positive timing effects between quarters and sales from its new hyaluronic acid facility in China as drivers.
Outlook
For the rest of the year Novozymes predicted that revenue growth in its biopharmaceutical business will slow down
“Biopharma sales grew very strongly in Q2 2012, partly due to timing between quarters, and, as a result, growth rates in Biopharma will decelerate in the second half of 2012.
The firm also said that the Swedish divestiture will continue to have a negative impact and predicted that – as a result - sales would be around DKK90m lower in the second half of 2012 than they were in the year earlier period.